Delhi High Court seeks Centre and regulators' replies on ranitidine safety-review petition
Published · Updated
What happened
The Delhi High Court asked the Centre and drug regulators to file replies on a petition seeking a time-bound completion of the ranitidine safety review. The petition argues that the review has remained pending for a long period despite safety concerns tied to the drug.
Why it matters
A court order requiring replies converts an administrative delay into a tracked legal process with near-term accountability for the Centre and regulators. If the government does not present a clear timeline or rationale, the matter can move toward judicial directions on regulatory action and public disclosure.
The Delhi High Court on November 5 sought replies from the Union government and drug regulators on a petition asking that the pending review of ranitidine's safety be completed within a fixed time frame. The case turns a long-running regulatory file into a live judicial matter, creating a near-term timetable for the Centre and the drug-control system to explain delay on a medicine linked in prior international scrutiny to probable carcinogenic risk. While the immediate subject is drug safety, the court step also opens a governance and accountability line that opposition parties or public-interest groups can use if the government appears slow or defensive.
Watch for
Delhi High Court cause-list update or next-hearing date for the ranitidine petition published on or after 2026-11-06 Union Health Ministry or CDSCO court filing stating a deadline for completing the ranitidine safety review DCGI or CDSCO public notice on ranitidine sales, testing, recall, or interim risk communication Attorney for the Centre seeking additional time in court on or before 2026-11-08 instead of filing a substantive reply
Sources
Researched and written by AI from the sources listed, under published rules. How V³ Aware is made